Western Pacific Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Western Pacific Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$180K	Hold	3,300	–	–	0.16%	65
2026 Q1	$157K	Hold	3,300	–	–	0.16%	70
2025 Q4	$173K	Hold	3,300	–	–	0.17%	66
2025 Q3	$214K	Buy	3,300 +2,800	+560%	+$161K	0.21%	60
2025 Q2	$24.3K	Sell	500 -500	-50%	-$19.4K	0.02%	151
2025 Q1	$34K	Hold	1,000	–	–	0.03%	142
2024 Q4	$39.4K	Buy	1,000 +500	+100%	+$23.6K	0.03%	146
2024 Q3	$23.5K	Buy	+500	New	+$25.4K	0.02%	186

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Western Pacific Wealth Management's CRSP Position: Q2 2026 in Review

Western Pacific Wealth Management held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 3,300 shares worth $180K. The position accounts for 0.16% of the portfolio, ranked #65.

Western Pacific Wealth Management first reported a position in CRSP in Q3 2024 and has held it in 8 quarters since. The position peaked at $214K in Q3 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Western Pacific Wealth Management held 3,300 shares of CRISPR Therapeutics worth $180K as of Q2 2026.
Western Pacific Wealth Management left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up 0.16% of Western Pacific Wealth Management's portfolio in Q2 2026, its #65 holding.
Western Pacific Wealth Management first reported a position in CRISPR Therapeutics in Q3 2024 and has held it in 8 quarters since.
Western Pacific Wealth Management's CRISPR Therapeutics position peaked at $214K in Q3 2025.
523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Western Pacific Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.